Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

October 31, 2025

Conditions
COVID-19
Interventions
BIOLOGICAL

Pfizer-BioNTech Standard dose

"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."

BIOLOGICAL

AstraZeneca Standard dose

"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"

BIOLOGICAL

Pfizer-BioNTech Fractional dose

"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."

BIOLOGICAL

AstraZeneca Fractional dose

"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"

BIOLOGICAL

Moderna Standard dose

Standard dose (50ug in 0.25ml)

BIOLOGICAL

Moderna Fractional dose

Fractional dose (20ug in 0.1ml)

Trial Locations (3)

Unknown

Puskesmas Ciumbuleuit, Bandung

Puskesmas Dago, Bandung

Puskesmas Garuda, Bandung

All Listed Sponsors
collaborator

Universitas Padjadjaran

OTHER

collaborator

Health Development Policy Agency, Ministry of Health Republic of Indonesia

UNKNOWN

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

The Peter Doherty Institute for Infection and Immunity

OTHER

collaborator

Indonesia University

OTHER

lead

Murdoch Childrens Research Institute

OTHER